GLP-1R drugs as a new approach for asthma in different body types
Official title: GLP-1R agonist immune targets in lean and obesity-associated asthma
Funded at Vanderbilt University Medical Center · NIH-11359691 · Data updated 2026-11-12
Researchers are testing whether popular diabetes drugs that activate GLP-1 receptors can reduce airway inflammation and help adults with asthma, including those who are lean or overweight.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | August 16, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $745,797 |
| NIH project number | 5R01AI182159-03 |
| Project ID | NIH-11359691 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with asthma, including both lean and obesity-associated phenotypes, who may be eligible for future GLP-1R–based therapies.
✕Less likely to help
Patients with asthma who do not respond to GLP-1R–targeted approaches or who have contraindications to GLP-1R agonists may not benefit.
What this research studies
This project looks at how GLP-1 receptor agonists, which are already approved for diabetes and obesity, might directly calm immune system activity that drives asthma. Scientists will study how these drugs affect platelets, T cells, and other immune components in both lean and obese individuals with asthma. The work combines preclinical experiments with clinical insights to pinpoint exactly where GLP-1 signaling reduces inflammation in the airways. The goal is to better translate these findings into safer, targeted use of GLP-1R agonists for asthma patients. If successful, the research could lead to new treatment options that complement existing therapies for different asthma phenotypes.
Why it matters
Potential benefit: Possibly faster access to more effective asthma treatments that work across patient body types by repurposing an existing diabetes drug.
How similar studies have gone: Prior data suggest GLP-1 signaling can modulate immune cell function, supporting potential benefits in asthma but human outcomes are still being explored.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Cahill, Katherine N — Vanderbilt University Medical Center
- Study coordinator: Cahill, Katherine N
Related research
Other NIH-funded projects on the same topics.
-
GLP-1 receptor agonists as immune targets to treat asthma in lean and obese adults
Aims to understand how GLP-1R‑agonist diabetes medicines may directly calm immune cells to reduce asthma in adults who are lean or obese.
-
Semaglutide for adults with obesity-related asthma
This trial gives adults with obesity-related asthma a daily oral semaglutide pill to test whether it improves asthma control and lowers airway and fat-tissue inflammation.
-
How high insulin in obesity may make airways tighten in asthma
This project looks at whether the higher insulin that comes with obesity makes airway nerves cause tighter breathing in people with obesity-related asthma.
-
Understanding how GLP-1 medicines help with asthma in people who are lean or have obesity
This project aims to discover how existing GLP-1 medicines, used for diabetes and obesity, can also help reduce inflammation in people with asthma.
-
Investigating a new treatment for asthma in adults with obesity
This study is looking at how a medication called GLP-1RA might help adults with asthma related to obesity by improving their breathing and reducing inflammation, and if you join, you'll take either the medication or a placebo for 12 weeks to see how it works for you.
-
Investigating the link between obesity, insulin resistance, and asthma severity
This study is looking at how insulin resistance, pre-diabetes, and diabetes impact asthma control in people with obesity who have asthma, especially those getting weight loss surgery, to help understand how these conditions might affect their breathing and overall health.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.